Tags » Lymphoma

Monitoring Minimal Residual Disease in Lymphoma: The Italian Experience

Paola Ghione, MD

Dr. Ghione is a visiting hematology fellow from Torino, Italy who is working with the Weill Cornell Lymphoma Program for six months. 606 more words
Patient Education

The Jas Journey 4 - My "To-Do" List: Thinking about Post-Treatment

As promised from my last post, here is my “to-do” list that has helped me get through my chemotherapy. During my bad days, this list would give me hope and would give me something to look forward to. 927 more words


FDA Approves First-Ever Targeted Marginal Zone Lymphoma Treatment

On January 19, 2017, the United States Food and Drug Administration (FDA) approved ibrutinib to treat patients that have received at least one line of prior therapy for marginal zone lymphoma (MZL), a type of non-Hodgkin lymphoma (NHL). 295 more words

Lymphoma News

The Fourteenth Tuesday: We Talk About the Hospital Slumber Party

WOW what a week it has been! So many firsts this week. And hopefully lasts. Usually the week I have between treatments is a calm one. 1,021 more words


Vipassana, here I come

During the Christmas period, staying at the Entrance most of the time, I had the privilege of being harmonized every day for nine days in a row – and also prayed for. 127 more words

In terms of genetics and progression, rapid FL progression is a distinct disease

Below is an interesting article about follicular lymphoma progression. It identifies three types of follicular lymphoma patients: those who progress slowly, those who progress rapidly (like my wife), and those who transform into DLBCL. 460 more words